识别新型乳腺癌生物标志物将改善患者分层，增强治疗效果，并有助于开发非侵入性诊断。我们比较了代表性乳腺癌细胞亚型的全细胞和外泌体样本的蛋白质组学特征，以评估细胞外囊泡作为液体活检中非侵袭性疾病生物标志物的潜力。总体而言，全细胞和外泌体样本中的差异表达蛋白（包括侵袭、转移、血管生成和耐药性标记）可以有效区分亚型；此外，我们的结果证实，外泌体的蛋白质组谱反映了乳腺癌细胞起源，这强调了它们作为疾病生物标志物的潜力。我们的研究将有助于识别支持乳腺癌患者分层的生物标志物并开发新的治疗策略。我们提供了一个开放的交互式网络工具来探索作为分子资源的数据，该资源可以解释这些蛋白质特征在乳腺癌分类中的作用。© 2024。作者。

Identifying novel breast cancer biomarkers will improve patient stratification, enhance therapeutic outcomes, and help develop non-invasive diagnostics. We compared the proteomic profiles of whole-cell and exosomal samples of representative breast cancer cell subtypes to evaluate the potential of extracellular vesicles as non-invasive disease biomarkers in liquid biopsies. Overall, differentially-expressed proteins in whole-cell and exosome samples (which included markers for invasion, metastasis, angiogenesis, and drug resistance) effectively discriminated subtypes; furthermore, our results confirmed that the proteomic profile of exosomes reflects breast cancer cell-of-origin, which underscores their potential as disease biomarkers. Our study will contribute to identifying biomarkers that support breast cancer patient stratification and developing novel therapeutic strategies. We include an open, interactive web tool to explore the data as a molecular resource that can explain the role of these protein signatures in breast cancer classification.© 2024. The Author(s).